Balaxi Q2 Revenue Up 45%, PAT Surges 450% YoY

Date: 12th November, 2026

Revenue from Operations: ₹8,137.23 lakh in Q2 FY27, compared to ₹5,617.53 lakh in Q2 FY26, representing a year-over-year growth of 44.85%.
EBITDA: ₹512.07 lakh in Q2 FY27, compared to ₹116.86 lakh in Q2 FY26, up 338.19% year-over-year.
EBITDA Margin: 6.29% in Q2 FY27, compared to 2.08% in Q2 FY26, an expansion of 421 basis points.
Profit After Tax (PAT): ₹115.01 lakh in Q2 FY27, compared to ₹20.90 lakh in Q2 FY26, up 450.29% year-over-year.
PAT Margin: 1.41% in Q2 FY27, compared to 0.37% in Q2 FY26, an expansion of 104 basis points.
Diluted EPS: ₹0.21 in Q2 FY27, compared to ₹0.04 in Q2 FY26, up 425.00% year-over-year.

Revenue from Operations: ₹16,205.40 lakh in H1 FY27, compared to ₹12,691.74 lakh in H1 FY26, representing a year-over-year growth of 27.68%.
EBITDA: ₹978.31 lakh in H1 FY27, compared to ₹531.71 lakh in H1 FY26, up 83.99% year-over-year.
EBITDA Margin: 6.04% in H1 FY27, compared to 4.19% in H1 FY26, an expansion of 185 basis points.
Profit After Tax (PAT): ₹244.76 lakh in H1 FY27, compared to ₹49.92 lakh in H1 FY26, up 390.30% year-over-year.
PAT Margin: 1.51% in H1 FY27, compared to 0.39% in H1 FY26, an expansion of 112 basis points.
Diluted EPS: ₹0.44 in H1 FY27, compared to ₹0.09 in H1 FY26, up 388.89% year-over-year.

Mr. Ashish Maheshwari, Chairman & Managing Director, commented that pharmaceutical markets in Africa and Latin America offer opportunities for companies with established distribution networks and diversified portfolios.
The company is focused on strengthening its presence through a branded, IPR-driven business model.
In H1 FY27, Balaxi added 31 new product registrations, enhancing its ability to address therapeutic requirements.
Latin America remains a key growth focus, with emphasis on markets like Guatemala, Dominican Republic, Honduras, and El Salvador.
Efforts are underway to improve operating efficiencies and cash conversion in Angola.
The Jadcherla manufacturing facility is now operational, marking the next phase of business development with priorities on in-house manufacturing, branded generics, and geographical expansion.

Balaxi Pharmaceuticals Limited is a branded, IPR-driven pharmaceutical company operating in frontier and semi-regulated markets across Africa and Latin America.
The company has over two decades of experience and an extensive product registration portfolio, warehousing infrastructure, and distribution network.
It operates through 38 warehouses, supported by over 500 professionals, including 80+ expatriate managers.
The product portfolio includes 1,001 registered products.
The Jadcherla facility in Telangana is designed to manufacture tablets and capsules, supporting manufacturing integration and expansion.

The document contains forward-looking statements subject to risks such as government actions and local developments.
Investor relations are handled by ORIM CONNECT at +(91) 82085 63201 or letsconnect@orim.in.